Attenuation of early and late phase allergen-induced bronchoconstriction in asthmatic subjects by a 5-lipoxygenase activating protein antagonist, BAYx 1005.

BACKGROUND: The cysteinyl leukotrienes (LTC4, LTD4 and LTE4) have been implicated in the pathogenesis of allergen-induced airway responses. The effects of pretreatment with BAYx 1005, an inhibitor of leukotriene biosynthesis via antagonism of 5-lipoxygenase activating protein, on allergen-induced early and late asthmatic responses has been evaluated. METHODS: Eight atopic subjects with mild asthma participated in a two period, double blind, placebo controlled, cross-over trial. Subjects were selected on the basis of a forced expiratory volume in one second (FEV1) of > 70% predicted, a methacholine provocative concentration causing a 20% fall in FEV1 (PC20) of < 32 mg/ ml, a documented allergen-induced early response (EAR, > 15% fall in FEV1 0-1 hour after allergen inhalation) and late response (LAR, > 15% fall in FEV1 3-7 hours after allergen inhalation), and allergen-induced airway hyperresponsiveness (at least a doubling dose reduction in the methacholine PC20 30 hours after allergen inhalation). During the treatment periods subjects received BAYx 1005 (500 mg twice daily) or placebo for 3.5 days; treatment periods were separated by at least two weeks. On the third day of treatment, two hours after administration of medication, subjects performed an allergen inhalation challenge and FEV1 was measured for seven hours. RESULTS: Treatment with BAYx 1005 attenuated the magnitude of both the allergen-induced early and late asthmatic responses. The mean (SE) maximal fall in FEV1 during the EAR was 26.6 (3.3)% during placebo treatment and 11.4 (3.3)% during treatment with BAYx 1005 (mean difference 15.2 (95% confidence interval (CI) 9.4 to 21.00) with a mean protection afforded by BAYx 1005 of 57.1%. The mean (SE) maximal fall in FEV1 during the LAR was 19.8 (5.7)% during placebo treatment and 10.7 (4.4)% during BAYx 1005 treatment (mean difference 9.2 (95% CI 1.4 to 17.0) with a mean protection afforded by BAYx 1005 of 46.0%. The area under the time response curve (AUC0-3) was also reduced after treatment with BAYx 1005 compared with placebo by 86.5%.h (mean difference 26.3 (95% CI 17.1 to 38.5)) and the AUC3-7 by 59.6%.h (mean difference 26.9 (95% CI-3.8 to 57.6)). CONCLUSIONS: These results show that antagonism of 5-lipoxygenase activating protein can attenuate allergen-induced bronchoconstrictor responses and support an important role for the cysteinyl leukotrienes in mediating these asthmatic responses.

[1]  S. Dahlén,et al.  Inhibition of allergen-induced airway obstruction and leukotriene generation in atopic asthmatic subjects by the leukotriene biosynthesis inhibitor BAYx 1005. , 1997, Thorax.

[2]  P. Sterk,et al.  The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo. , 1995, The Journal of allergy and clinical immunology.

[3]  W. Henderson.  The Role of Leukotrienes in Inflammation , 1994, Annals of Internal Medicine.

[4]  A. Williams,et al.  Effect of the 5-lipoxygenase inhibitor ZD2138 on allergen-induced early and late asthmatic responses. , 1994, Thorax.

[5]  C. Labat,et al.  (R)-2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl] acetic acid (BAY x1005), a potent leukotriene synthesis inhibitor: effects on anti-IgE challenge in human airways. , 1994, The Journal of pharmacology and experimental therapeutics.

[6]  B. Beckermann,et al.  BAY X1005, a new inhibitor of leukotriene synthesis: in vivo inflammation pharmacology and pharmacokinetics. , 1993, The Journal of pharmacology and experimental therapeutics.

[7]  T. Haahtela,et al.  Leukotriene E4 and granulocytic infiltration into asthmatic airways , 1993, The Lancet.

[8]  P. Sterk,et al.  Oral leukotriene inhibitor (MK-886) blocks allergen-induced airway responses. , 1993, The American review of respiratory disease.

[9]  A. Hatzelmann,et al.  Mode of action of the new selective leukotriene synthesis inhibitor BAY X 1005 ((R)-2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl acetic acid) and structurally related compounds. , 1993, Biochemical pharmacology.

[10]  D. Margolskee,et al.  Leukotriene D4 receptor blockade inhibits the immediate and late bronchoconstrictor responses to inhaled antigen in patients with asthma. , 1992, The Journal of allergy and clinical immunology.

[11]  C. Dollery,et al.  Effect of cysteinyl-leukotriene receptor antagonist ICI 204.219 on allergen-induced bronchoconstriction and airway hyperreactivity in atopic subjects , 1991, The Lancet.

[12]  Paul H. Rubin,et al.  Effect of a 5-lipoxygenase inhibitor on leukotriene generation and airway responses after allergen challenge in asthmatic patients. , 1991, Thorax.

[13]  P. O'Byrne,et al.  Urinary leukotriene E4 levels during early and late asthmatic responses. , 1990, The Journal of allergy and clinical immunology.

[14]  S. Wenzel,et al.  Elevated levels of leukotriene C4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge. , 1990, The American review of respiratory disease.

[15]  C. Dollery,et al.  URINARY LEUKOTRIENE E4 AFTER ANTIGEN CHALLENGE AND IN ACUTE ASTHMA AND ALLERGIC RHINITIS , 1989, The Lancet.

[16]  J. Arm,et al.  The effects of inhaled leukotriene E4 on the airway responsiveness to histamine in subjects with asthma and normal subjects. , 1988, The Journal of allergy and clinical immunology.

[17]  D. Cockcroft,et al.  Prediction of airway responsiveness to allergen from skin sensitivity to allergen and airway responsiveness to histamine. , 2015, The American review of respiratory disease.

[18]  J. Drazen,et al.  Leukotrienes and airway responses. , 1987, The American review of respiratory disease.

[19]  E. R. Mcfadden,et al.  Bronchoconstrictor effects of leukotriene E4 in normal and asthmatic subjects. , 1987, The American review of respiratory disease.

[20]  P. O'Byrne,et al.  Airway responsiveness to leukotrienes C4 and D4 and to methacholine in patients with asthma and normal controls. , 1986, The New England journal of medicine.

[21]  H. Sluiter,et al.  Bronchoalveolar eosinophilia during allergen-induced late asthmatic reactions. , 1985, The American review of respiratory disease.

[22]  N. Barnes,et al.  Comparative effects of inhaled leukotriene C4, leukotriene D4, and histamine in normal human subjects. , 1984, Thorax.

[23]  M. Wasserman,et al.  Investigation of leukotriene involvement in the vasopermeability response associated with guinea pig tracheal anaphylaxis: comparison with cutaneous anaphylaxis. , 1983, European journal of pharmacology.

[24]  H. G. Johnson,et al.  Secretogogue responses of leukotriene C4, D4: comparison of potency in canine trachea in vivo. , 1983, Prostaglandins.

[25]  J. Shelhamer,et al.  Slow-reacting substances, leukotrienes C4 and D4, increase the release of mucus from human airways in vitro. , 2015, The American review of respiratory disease.

[26]  N. Thomson,et al.  Allergen-induced increase in bronchial responsiveness to histamine: relationship to the late asthmatic response and change in airway caliber. , 1982, The Journal of allergy and clinical immunology.

[27]  P. Paré,et al.  Slow-reacting substances (leukotrienes) contract human airway and pulmonary vascular smooth muscle in vitro , 1981, Nature.

[28]  Bengt Samuelsson,et al.  Leukotrienes are potent constrictors of human bronchi , 1980, Nature.

[29]  M. Hills,et al.  The two-period cross-over clinical trial. , 1979, British journal of clinical pharmacology.

[30]  D. Cockcroft,et al.  154. Allergen-induced increase in nonallergic (nonspecific) bronchial reactivity; its relation to the late asthmatic response , 1978 .

[31]  D. Cockcroft,et al.  Allergen‐induced increase in non‐allergic bronchial reactivity , 1977, Clinical allergy.

[32]  F. Hargreave,et al.  Bronchial reactivity to inhaled histamine: a method and clinical survey , 1977, Clinical allergy.

[33]  J. Morris,et al.  Spirometric standards for healthy nonsmoking adults. , 2015, The American review of respiratory disease.